Simcor is a drug owned by Abbvie Inc. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 15, 2018. Details of Simcor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(8 years ago) |
Expired
|
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(8 years ago) |
Expired
|
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(12 years ago) |
Expired
|
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(12 years ago) |
Expired
|
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(12 years ago) |
Expired
|
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(12 years ago) |
Expired
|
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(12 years ago) |
Expired
|
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(12 years ago) |
Expired
|
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Simcor's patents.
Latest Legal Activities on Simcor's Patents
Given below is the list of recent legal activities going on the following patents of Simcor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 11 Sep, 2015 | US7998506 |
| Correspondence Address Change | 01 Jul, 2013 | US7998506 |
| Email Notification | 07 Oct, 2011 | US7998506 |
| Change in Power of Attorney (May Include Associate POA) | 07 Oct, 2011 | US7998506 |
| Patent Issue Date Used in PTA Calculation | 16 Aug, 2011 | US7998506 |
| Recordation of Patent Grant Mailed | 16 Aug, 2011 | US7998506 |
| Email Notification | 28 Jul, 2011 | US7998506 |
| Issue Notification Mailed | 27 Jul, 2011 | US7998506 |
| Application Is Considered Ready for Issue | 13 Jul, 2011 | US7998506 |
| Dispatch to FDC | 13 Jul, 2011 | US7998506 |
US patents provide insights into the exclusivity only within the United States, but
Simcor is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Simcor's family patents as well as insights into
ongoing legal events
on those patents.
Simcor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Simcor's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 15, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Simcor Generics:
There are no approved generic versions for Simcor as of now.
Alternative Brands for Simcor
Simcor which is used for lowering cholesterol and triglyceride levels and increasing HDL cholesterol in patients with specific conditions., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
About Simcor
Simcor is a drug owned by Abbvie Inc. It is used for lowering cholesterol and triglyceride levels and increasing HDL cholesterol in patients with specific conditions. Simcor uses Niacin; Simvastatin as an active ingredient. Simcor was launched by Abbvie in 2008.
Approval Date:
Simcor was approved by FDA for market use on 15 February, 2008.
Active Ingredient:
Simcor uses Niacin; Simvastatin as the active ingredient. Check out other Drugs and Companies using Niacin; Simvastatin ingredient
Treatment:
Simcor is used for lowering cholesterol and triglyceride levels and increasing HDL cholesterol in patients with specific conditions.
Dosage:
Simcor is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG;20MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 500MG;40MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 1GM;20MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 1GM;40MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 750MG;20MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |